RecruitingPhase 3NCT06830421
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Freiburg
- Intervention
- R-MP and Procarbazine maintenance(drug)
- Enrollment
- 340 target
- Eligibility
- 65 years · All sexes
- Timeline
- 2023 – 2031
Study locations (30)
- University Hospital Freiburg, Department Medicine I, Hematology, oncology and stem cell transplantation, Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-Stihl, Stuttgart, Baden-Wurttemberg, Germany
- University Hospital Aachen, Aachen, Germany
- University Hospital Augsburg, Augsburg, Germany
- Helios Klinikum Berlin-Buch, Berlin, Germany
- University Hospital Berlin, Berlin, Germany
- Evangelisches Klinikum Bethel, Bielefeld, Germany
- Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany
- Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany
- Klinikum Bremen-Mitte gGmbH, Bremen, Germany
- Klinikum Chemnitz gGmbH, Chemnitz, Germany
- Universitätsklinikum Köln, Cologne, Germany
- Carl Gustav Carus Universitätsklinikum Dresden, Dresden, Germany
- Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- Universitätsklinikum Erlangen, Erlangen, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
German Federal Ministry of Education and Research · University Hospital Tuebingen · Heinrich-Heine University, Duesseldorf · Klinikum Stuttgart · University of Kaiserslautern · University Hospital Munich · University Hospital Regensburg
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06830421 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation
- RECRUITINGPHASE1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center
See all trials for Primary central nervous system lymphoma →